547 related articles for article (PubMed ID: 28805815)
21. Clonal evolution of glioblastoma under therapy.
Wang J; Cazzato E; Ladewig E; Frattini V; Rosenbloom DI; Zairis S; Abate F; Liu Z; Elliott O; Shin YJ; Lee JK; Lee IH; Park WY; Eoli M; Blumberg AJ; Lasorella A; Nam DH; Finocchiaro G; Iavarone A; Rabadan R
Nat Genet; 2016 Jul; 48(7):768-76. PubMed ID: 27270107
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.
Riganti C; Salaroglio IC; Caldera V; Campia I; Kopecka J; Mellai M; Annovazzi L; Bosia A; Ghigo D; Schiffer D
Neuro Oncol; 2013 Nov; 15(11):1502-17. PubMed ID: 23897632
[TBL] [Abstract][Full Text] [Related]
23. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
[TBL] [Abstract][Full Text] [Related]
24. Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress.
Hegge B; Sjøttem E; Mikkola I
BMC Cancer; 2018 May; 18(1):496. PubMed ID: 29716531
[TBL] [Abstract][Full Text] [Related]
25. Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries.
Rocha CRR; Reily Rocha A; Molina Silva M; Rodrigues Gomes L; Teatin Latancia M; Andrade Tomaz M; de Souza I; Karolynne Seregni Monteiro L; Menck CFM
Cells; 2020 Dec; 9(12):. PubMed ID: 33271924
[TBL] [Abstract][Full Text] [Related]
26. A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65.
Putz F; Knippen S; Lahmer G; Fietkau R; Semrau S
Am J Clin Oncol; 2017 Oct; 40(5):523-529. PubMed ID: 26017481
[TBL] [Abstract][Full Text] [Related]
27. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
Wang X; Chen JX; Liu YH; You C; Mao Q
Neurol Sci; 2013 Aug; 34(8):1421-8. PubMed ID: 23224642
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Gao Y; Fotovati A; Lee C; Wang M; Cote G; Guns E; Toyota B; Faury D; Jabado N; Dunn SE
Mol Cancer Ther; 2009 Dec; 8(12):3276-84. PubMed ID: 19996271
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
[TBL] [Abstract][Full Text] [Related]
30. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S
Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225
[TBL] [Abstract][Full Text] [Related]
31. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
32. MGMT gene silencing and benefit from temozolomide in glioblastoma.
Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R
N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010
[TBL] [Abstract][Full Text] [Related]
33. In vivo CRISPR screening for novel noncoding RNA functional targets in glioblastoma models.
Attenello FJ; Tsung K; Bishara I; Loh YE; Chen TC
J Neurosci Res; 2021 Sep; 99(9):2029-2045. PubMed ID: 33969526
[TBL] [Abstract][Full Text] [Related]
34. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
35. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
Zhang W; Zhang J; Hoadley K; Kushwaha D; Ramakrishnan V; Li S; Kang C; You Y; Jiang C; Song SW; Jiang T; Chen CC
Neuro Oncol; 2012 Jun; 14(6):712-9. PubMed ID: 22570426
[TBL] [Abstract][Full Text] [Related]
36. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
37. Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells.
Tsukamoto Y; Ohtsu N; Echizenya S; Otsuguro S; Ogura R; Natsumeda M; Isogawa M; Aoki H; Ichikawa S; Sakaitani M; Matsuda A; Maenaka K; Fujii Y; Kondo T
Stem Cells; 2016 Aug; 34(8):2016-25. PubMed ID: 27090194
[TBL] [Abstract][Full Text] [Related]
38. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
39. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
40. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Tran AN; Lai A; Li S; Pope WB; Teixeira S; Harris RJ; Woodworth DC; Nghiemphu PL; Cloughesy TF; Ellingson BM
Neuro Oncol; 2014 Mar; 16(3):414-20. PubMed ID: 24305712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]